Reported 1 day ago
CoreWeave saw its first downgrade since its IPO to Equal Weight by Barclays due to valuation concerns, yet its stock has risen. Conversely, Rocket Pharmaceuticals faces a significant drop after the FDA paused its gene therapy trial following a patient's death. Meanwhile, SoundHound AI received an Overweight rating from Piper Sandler, predicting robust growth in the AI audio market.
Source: YAHOO